Literature DB >> 22002259

Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study.

Sandip Gurav1, Ravindra Punde, Junaid Farooqui, Mohd Zainuddin, Sriram Rajagopal, Ramesh Mullangi.   

Abstract

A highly sensitive, rapid assay method has been developed and validated for the estimation of abiraterone (ART) in rat and human plasma with liquid chromatography coupled to tandem mass spectrometry and electrospray ionization in the positive-ion mode. The assay procedure involves extraction of ART and phenacetin (internal standard, IS) from rat and human plasma with a simple protein precipitation extraction process. Chromatographic separation was achieved using an isocratic mobile (10 mm ammonium acetate:acetonitrile, 10:90, v/v) at a flow-rate of 0.70 mL/min on an Atlantis dC(18) column maintained at 40 °C with a total run time of 3.5 min. The MS/MS ion transitions monitored were 350.3 → 156.0 for ART and 180.2 → 110.1 for IS. Method validation was performed as per FDA guidelines and the results met the acceptance criteria. The lower limit of quantitation achieved was 0.20 ng/mL and the linearity range extended from 0.20 to 201 ng/mL. The intra- and inter-day precisions were in the ranges 2.39-10.4 and 4.84-9.53% in rat plasma and 3.82-10.8 and 6.97-8.94% in human plasma.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002259     DOI: 10.1002/bmc.1726

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  6 in total

1.  Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.

Authors:  Kyu-Pyo Kim; Robert A Parise; Julianne L Holleran; Lionel D Lewis; Leonard Appleman; Nielka van Erp; Michael J Morris; Jan H Beumer
Journal:  J Pharm Biomed Anal       Date:  2017-02-13       Impact factor: 3.935

2.  β-Cyclodextrin sensitized spectrofluorimetry for the determination of abiraterone acetate and abiraterone.

Authors:  Aiqin Gong; Xiashi Zhu
Journal:  J Fluoresc       Date:  2013-07-10       Impact factor: 2.217

3.  Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.

Authors:  Guillemette E Benoist; Eric van der Meulen; Floor J E Lubberman; Winald R Gerritsen; Tineke J Smilde; Jack A Schalken; Jan H Beumer; David M Burger; Nielka P van Erp
Journal:  Biomed Chromatogr       Date:  2017-05-16       Impact factor: 1.902

4.  AQbD Driven Development of an RP-HPLC Method for the Quantitation of Abiraterone Acetate for its Pharmaceutical Formulations in the Presence of Degradants.

Authors:  Bikash Ranjan Jena; Siva Prasad Panda; Umasankar Kulandaivelu; Rajasekhar Reddy Alavala; G S N Koteswara Rao; Suryakanta Swain; Gurudutta Pattnaik; Debashish Ghose
Journal:  Turk J Pharm Sci       Date:  2021-12-31

5.  Biotransformation of Abiraterone Into Five Characteristic Metabolites by the Rat Gut Microbiota and Liver Microsomes.

Authors:  Adili Keranmu; Fei-Ya Yang; Wasilijiang Wahafu; Su-Jun Han; Guo-Sheng Yang; Nian-Zeng Xing
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

6.  Pharmacokinetic Variability in Pre-Clinical Studies: Sample Study with Abiraterone in Rats and Implications for Short-Term Comparative Pharmacokinetic Study Designs.

Authors:  Jana Královičová; Aleš Bartůněk; Jiří Hofmann; Tomáš Křížek; Petr Kozlík; Jaroslava Roušarová; Pavel Ryšánek; Martin Šíma; Ondřej Slanař
Journal:  Pharmaceutics       Date:  2022-03-15       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.